To the Editor: Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (vancomycin-intermediate S. aureus, or VISA) was initially described in Japan,1 then the United States,2 and subsequently other regions of the world. Recently, Ward and colleagues reported the initial Australian isolate — a heteroresistant VISA (hVISA) strain — in Melbourne, Victoria.3 We report the first isolation of hVISA in Sydney, New South Wales.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
